Search

Biophytum sensitivum linn. (Oxalidaceae), is an important and widely used medicinal plant. Biophytum sensitivum linn. is used as a traditional folk medicine in ailments such as inflammation, arthritis, wounds, tumors and burns, gonorrhea, stomach ache, asthma, cough, degenerative joint disease, urinary calculi, diabetes, snake bite, amenorrhea and dysmenorrhea.. The total flavonoid content of methanolic whole plant extract of B. sensitivum (MEBS) was determined by using aluminium chloride colorimetric method. Flavonoid compounds were found to be 9.49 µg of quercetin equivalent [QE] per mg of methanolic whole plant extract of Biophytum sensitivum. In this study phytochemical analysis of methanolic extract of B. sensitivum L. has indicated the presence of flavonoid . Since these compounds are of pharmacological interest, coupled with the use of this plant in traditional medicine, it prompted us to check B.sensitivum  L. for possible antioxidant activity by DPPH scavenging activity and reducing power ability. The maximum percentage inhibition by DPPH method was found about 43.96 at concentration of 110.46µg/ml, when compared with Quercetin. The reducing capabilities were found to be in dose dependent manner. Key words: Biophytum sensitivum, aluminium chloride, quercetin, DPPH.

The electro-magnetic equations of Maxwell and the equations of elasticity have been used to investigate the disturbances in an elastic bar acted upon by a magnetic field.

Two hundred and nine children (20 years and below) diagnosed as acute lymphoblastic leukemia between January 1980 and December 1983 were retrospectively analysed to evaluate the clinical features, prognostic factors and the results of therapy. One hundred and eighty one evaluable patients were treated with three different chemotherapy regimens consisting of vincristine and prednisolone (Group-A), vincristine, prednisolone and L-asparaginase (Group B-60 patients), and vincristine, prednisolone and adriamycin (Group C-81 patients). Complete remission was achieved in 152 (84%) patients, remission induction being 75 percent, 85 percent and 88 percent in Group A, B and C respectively. At a median follow-up of 36 months the disease free survival for complete responders was 35.5 patient. The disease-free survival for Group A, B and C was 20 percent, 47 percent 34 percent respectively indicating the superiority of a three drug regimen over the conventional two drug regimen. Patients at standard risk in each group had significantly better survival when compared to those at high risk. A 3-drug treatment regimen was superior to the 2-drug regimen and a low initial leucocyte count was an important favourable prognostic factor.

One hundred fifty patients with nasopharyngeal carcinoma were treated at the Tata Memorial Hospital from January 1980 to December 1984. Lymphoepithelioma was the most common histologic subtype. Advanced disease in stages III and IV was seen in 22.66% and 72% of the patients, respectively. Complete remission was obtained in 80 of 120 patients (66.66%) with radiation alone and in 19 of 30 patients (63.3%) who received preradiation chemotherapy and radiation. Age, sex, and histology did not influence the rate of complete remission. The N0-1 nodal status group had a significantly better response of 81% and 36% survival, as compared with the N2-3 group with a 55% response and 20% survival. Only 30 of those who received radiation alone and 10 of those who received preradiation chemotherapy are disease-free for a median period of 24 months. Twenty-six relapses have occurred within a median period of 12 months. The 5-year actuarial disease-free survival is 13%. This indicates the need for an early diagnosis and combined aggressive treatment to improve survival.